Similar rates of acute kidney injury and hospital survival in patients with multivessel CAD presenting with AMI and cardiogenic shock who were on early MCS treated with culprit vessel-only vs multivessel PCI.
Among patients with heart failure, men have higher plasma concentrations of angiotensin-converting enzyme 2.
Acute decompensated heart failure in children is characterized by high burdens of comorbidities, mortality, and frequent readmission, especially among patients with underlying congenital heart disease.
Baseline NT-proBNP levels were found to predict hospitalizations for heart failure (HF) and cardiovascular death in patients with HF with preserved ejection fraction.
Heart transplant with or without bridge to transplant LVAD therapy was found to be associated with greater 5-year survival compared with LVAD destination therapy in patients with end-stage heart failure.
The FDA has granted Fast Track designation to omecamtiv mecarbil (Amgen) for the potential treatment of chronic heart failure with reduced ejection fraction (HFrEF).
Oral anticoagulation with or without antiplatelet medication was found to increase the risk for bleeding, with minimal protective effect against ischemic stroke in patients with heart failure with reduced ejection fraction and sinus rhythm.
The FDA has approved Farxiga (dapagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction with and without type 2 diabetes.
Primary percutaneous coronary intervention (PCI) remains the standard of care for patients with ST-elevation myocardial infarction (STEMI) during the COVID-19 pandemic.
The presence of collateral vessels was not found to correlate with reciprocal ST-segment depression in opposite leads in patients who underwent primary percutaneous coronary intervention for first time acute ST-segment elevation myocardial infarction.